Condition (MeSH)
Gyrate Atrophy
ClinicalTrials.gov lists 17 trials for Gyrate Atrophy or a narrower condition beneath it. National Eye Institute (NEI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
17 of the 17 trials are tagged with Gyrate Atrophy itself; the rest are tagged with a narrower condition beneath it.
When did Gyrate Atrophy trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2010 | 2 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 17 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Gyrate Atrophy trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Not applicable | 10 |
| Observational | 5 |
How many Gyrate Atrophy trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 2 |
| Completed | 9 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Gyrate Atrophy trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Eye Institute (NEI) | 2 |
| Faculty Hospital Kralovske Vinohrady | 1 |
| Heinz Italia SpA | 1 |
| PepsiCo Global R&D | 1 |
Which drugs are being tested for Gyrate Atrophy? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Docosahexaenoic Acid | 1 |
Interventions as named in the registry (1)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Gene Therapy | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Gyrate Atrophy? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina. | Proceedings of the National Academy of Sciences of the United States of America | 2000 | Yes |
| Ornithine delta-aminotransferase mutations in gyrate atrophy. Allelic heterogeneity and functional consequences. | The Journal of biological chemistry | 1992 | Yes |
| Gyrate atrophy of the choroid and retina. Long-term reduction of ornithine slows retinal degeneration. | Archives of ophthalmology (Chicago, Ill. : 1960) | 1991 | Yes |
| Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. | Ophthalmology | 2003 | No |
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Gyrate atrophy of choroid and retina | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Gyrate atrophy of choroid and retina | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Gyrate atrophy of choroid and retina | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Gyrate atrophy of choroid and retina | Cases families | Worldwide | Not stated | Unspecified | |
| Gyrate atrophy of choroid and retina | Point prevalence | 1-9 / 100 000 | Finland | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Gyrate atrophy of choroid and retina | 414 | Exact | Orphadata Science knowledge files, Product 1 |
| Gyrate atrophy of choroid and retina | 414 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.